Atara Biotherapeutics’ Strategic Agreement with Pierre Fabre

McDermott Will & Emery advised Pierre Fabre on the deal.

Pierre Fabre finalized a strategic collaboration with Atara Biotherapeutics to commercialize Tab-cel® in Europe, the Middle East, Africa and other selected emerging markets for Epstein-Barr virus (EBV) positive cancers.

Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and up to approximately USD 320 million in additional regulatory and sales milestone payments, plus significant double-digit tiered royalties as a percentage of net sales.

Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world, the 2nd largest private French pharmaceutical group and the market leader in France for products sold over the counter in pharmacies. 

Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. 

The McDermott team that advised Pierre Fabre included Emmanuelle Trombe (Picture), Anne-France Moreau (partners) and Edouard Becker (associate).

Involved fees earner: Edouard Becker – McDermott Will & Emery; Anne-France Moreau – McDermott Will & Emery; Emmanuelle Trombe – McDermott Will & Emery;

Law Firms: McDermott Will & Emery;

Clients: Pierre Fabre S.A.;

Author: Naoual Sadouqi